606 related articles for article (PubMed ID: 33750801)
1. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract][Full Text] [Related]
2. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
4. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
6. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
7. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
10. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
11. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
[TBL] [Abstract][Full Text] [Related]
12. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
14. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
16. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
[TBL] [Abstract][Full Text] [Related]
17. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
19. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
20. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
